With a constantly increasing incidence,cutaneous melanoma has raised the need for a better understanding of its complex microenvironment that may further guide therapeutic options.Melanoma is a model tumor in immuno-o...With a constantly increasing incidence,cutaneous melanoma has raised the need for a better understanding of its complex microenvironment that may further guide therapeutic options.Melanoma is a model tumor in immuno-oncology.Inflammation represents an important hallmark of cancer capable of inducing and sustaining tumor development.The inflammatory process also orchestrates the adaptative immunosuppression of tumor cells that helps them to evade immune destruction.Besides its role in proliferation,angiogenesis,and apoptosis,cyclooxygenase-2(COX-2)is a well-known promoter of immune suppression in melanoma.COX-2 inhibitors are closely involved in this condition.This review attempts to answer two controversial questions:is COX-2 a valuable prognostic factor?Among all COX-2 inhibitors,is celecoxib a suitable adjuvant in melanoma therapy?展开更多
基金supported by grants from“Iuliu Ha(t)ieganu”University of Medicine and Pharmacy,Cluj-Napoca,Romania(Grant No.1680/84/19.01.2018)European Social Found,Human Capital Operational Programme 2014-2020(Grant No.POCU/380/6/13/125171)。
文摘With a constantly increasing incidence,cutaneous melanoma has raised the need for a better understanding of its complex microenvironment that may further guide therapeutic options.Melanoma is a model tumor in immuno-oncology.Inflammation represents an important hallmark of cancer capable of inducing and sustaining tumor development.The inflammatory process also orchestrates the adaptative immunosuppression of tumor cells that helps them to evade immune destruction.Besides its role in proliferation,angiogenesis,and apoptosis,cyclooxygenase-2(COX-2)is a well-known promoter of immune suppression in melanoma.COX-2 inhibitors are closely involved in this condition.This review attempts to answer two controversial questions:is COX-2 a valuable prognostic factor?Among all COX-2 inhibitors,is celecoxib a suitable adjuvant in melanoma therapy?
